Company intelligence / Profile preview

Altar

Evry, Île-de-France, France

Ownership: Private
Employees: ~14
Development stage: Other

Overview

Altar specialized in the development of microorganisms using its proprietary adaptive laboratory evolution platform for industrial and health-related applications but did not have a clinical pipeline per se; its platform supports microbial strain improvement for bioproduction and health, now fully integrated into Lesaffre as of late 2024.

Modalities: Microbial therapyEnzyme replacement therapyBiologic
Industry: Non-Drug Biotech

Partnerships

Ginkgo BioworksEuropean Commission (EIC Accelerator Pilot)French Alternative Energies and Atomic Energy Commission (CEA)

Beyond the preview

Go deeper on Altar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altar.

Explore the full profile